Selected research
Industry Research
Statin Industry Research Report 2026
Market perspective
The global Statin market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Statin market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Statin market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Statin market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Statin include CHIA TAI TIANQING, Zhejiang Jingxin Pharmaceutical, Shanghai Shyndec Pharmaceutical, Henan Topfond Pharmaceutical, Novartis, Merck, LUNAN BETTER, Livzon Pharmaceutical and Wanbang Biopharmaceuticals, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Statin market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Statin.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Statin Market by Company
CHIA TAI TIANQING
Zhejiang Jingxin Pharmaceutical
Shanghai Shyndec Pharmaceutical
Henan Topfond Pharmaceutical
Novartis
Merck
LUNAN BETTER
Livzon Pharmaceutical
Wanbang Biopharmaceuticals
Pfizer
Huizhi
China Resources Double-Crane Pharmaceutical
North China Pharmaceutical
Hanhui Pharmaceutical
Daiichi Sankyo
Beijing Jialin Pharmaceutical
AstraZeneca
Statin Segment by Type
Astrovastatin
Pitavastatin
Rosuvastatin
Others
Statin Segment by Application
Inflammatory Disorders
Cardiovascular Disorders
Obesity
Others
Statin Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Statin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Statin and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Statin.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Statin companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Astrovastatin
- Pitavastatin
- Rosuvastatin
- Others
Applications
- Inflammatory Disorders
- Cardiovascular Disorders
- Obesity
- Others
Companies covered
- CHIA TAI TIANQING
- Zhejiang Jingxin Pharmaceutical
- Shanghai Shyndec Pharmaceutical
- Henan Topfond Pharmaceutical
- Novartis
- Merck
- LUNAN BETTER
- Livzon Pharmaceutical
- Wanbang Biopharmaceuticals
- Pfizer
- Huizhi
- China Resources Double-Crane Pharmaceutical
- North China Pharmaceutical
- Hanhui Pharmaceutical
- Daiichi Sankyo
- Beijing Jialin Pharmaceutical
- AstraZeneca
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Statin by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Astrovastatin
- 2.2.3 Pitavastatin
- 2.2.4 Rosuvastatin
- 2.2.5 Others
- 2.3 Statin by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Inflammatory Disorders
- 2.3.3 Cardiovascular Disorders
- 2.3.4 Obesity
- 2.3.5 Others
- 2.4 Assumptions and Limitations
3 Statin Breakdown Data by Type
- 3.1 Global Statin Historic Market Size by Type (2021-2026)
- 3.2 Global Statin Forecasted Market Size by Type (2027-2032)
4 Statin Breakdown Data by Application
- 4.1 Global Statin Historic Market Size by Application (2021-2026)
- 4.2 Global Statin Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Statin Market Perspective (2021-2032)
- 5.2 Global Statin Growth Trends by Region
- 5.2.1 Global Statin Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Statin Historic Market Size by Region (2021-2026)
- 5.2.3 Statin Forecasted Market Size by Region (2027-2032)
- 5.3 Statin Market Dynamics
- 5.3.1 Statin Industry Trends
- 5.3.2 Statin Market Drivers
- 5.3.3 Statin Market Challenges
- 5.3.4 Statin Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Statin Players by Revenue
- 6.1.1 Global Top Statin Players by Revenue (2021-2026)
- 6.1.2 Global Statin Revenue Market Share by Players (2021-2026)
- 6.2 Global Statin Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Statin Head Office and Area Served
- 6.4 Global Statin Players, Product Type & Application
- 6.5 Global Statin Manufacturers Established Date
- 6.6 Global Statin Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Statin Market Size (2021-2032)
- 7.2 North America Statin Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Statin Market Size by Country (2021-2026)
- 7.4 North America Statin Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Statin Market Size (2021-2032)
- 8.2 Europe Statin Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Statin Market Size by Country (2021-2026)
- 8.4 Europe Statin Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Statin Market Size (2021-2032)
- 9.2 Asia-Pacific Statin Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Statin Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Statin Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Statin Market Size (2021-2032)
- 10.2 South America Statin Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Statin Market Size by Country (2021-2026)
- 10.4 South America Statin Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Statin Market Size (2021-2032)
- 11.2 Middle East & Africa Statin Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Statin Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Statin Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 CHIA TAI TIANQING
- 12.1.1 CHIA TAI TIANQING Company Information
- 12.1.2 CHIA TAI TIANQING Business Overview
- 12.1.3 CHIA TAI TIANQING Revenue in Statin Business (2021-2026)
- 12.1.4 CHIA TAI TIANQING Statin Product Portfolio
- 12.1.5 CHIA TAI TIANQING Recent Developments
- 12.2 Zhejiang Jingxin Pharmaceutical
- 12.2.1 Zhejiang Jingxin Pharmaceutical Company Information
- 12.2.2 Zhejiang Jingxin Pharmaceutical Business Overview
- 12.2.3 Zhejiang Jingxin Pharmaceutical Revenue in Statin Business (2021-2026)
- 12.2.4 Zhejiang Jingxin Pharmaceutical Statin Product Portfolio
- 12.2.5 Zhejiang Jingxin Pharmaceutical Recent Developments
- 12.3 Shanghai Shyndec Pharmaceutical
- 12.3.1 Shanghai Shyndec Pharmaceutical Company Information
- 12.3.2 Shanghai Shyndec Pharmaceutical Business Overview
- 12.3.3 Shanghai Shyndec Pharmaceutical Revenue in Statin Business (2021-2026)
- 12.3.4 Shanghai Shyndec Pharmaceutical Statin Product Portfolio
- 12.3.5 Shanghai Shyndec Pharmaceutical Recent Developments
- 12.4 Henan Topfond Pharmaceutical
- 12.4.1 Henan Topfond Pharmaceutical Company Information
- 12.4.2 Henan Topfond Pharmaceutical Business Overview
- 12.4.3 Henan Topfond Pharmaceutical Revenue in Statin Business (2021-2026)
- 12.4.4 Henan Topfond Pharmaceutical Statin Product Portfolio
- 12.4.5 Henan Topfond Pharmaceutical Recent Developments
- 12.5 Novartis
- 12.5.1 Novartis Company Information
- 12.5.2 Novartis Business Overview
- 12.5.3 Novartis Revenue in Statin Business (2021-2026)
- 12.5.4 Novartis Statin Product Portfolio
- 12.5.5 Novartis Recent Developments
- 12.6 Merck
- 12.6.1 Merck Company Information
- 12.6.2 Merck Business Overview
- 12.6.3 Merck Revenue in Statin Business (2021-2026)
- 12.6.4 Merck Statin Product Portfolio
- 12.6.5 Merck Recent Developments
- 12.7 LUNAN BETTER
- 12.7.1 LUNAN BETTER Company Information
- 12.7.2 LUNAN BETTER Business Overview
- 12.7.3 LUNAN BETTER Revenue in Statin Business (2021-2026)
- 12.7.4 LUNAN BETTER Statin Product Portfolio
- 12.7.5 LUNAN BETTER Recent Developments
- 12.8 Livzon Pharmaceutical
- 12.8.1 Livzon Pharmaceutical Company Information
- 12.8.2 Livzon Pharmaceutical Business Overview
- 12.8.3 Livzon Pharmaceutical Revenue in Statin Business (2021-2026)
- 12.8.4 Livzon Pharmaceutical Statin Product Portfolio
- 12.8.5 Livzon Pharmaceutical Recent Developments
- 12.9 Wanbang Biopharmaceuticals
- 12.9.1 Wanbang Biopharmaceuticals Company Information
- 12.9.2 Wanbang Biopharmaceuticals Business Overview
- 12.9.3 Wanbang Biopharmaceuticals Revenue in Statin Business (2021-2026)
- 12.9.4 Wanbang Biopharmaceuticals Statin Product Portfolio
- 12.9.5 Wanbang Biopharmaceuticals Recent Developments
- 12.10 Pfizer
- 12.10.1 Pfizer Company Information
- 12.10.2 Pfizer Business Overview
- 12.10.3 Pfizer Revenue in Statin Business (2021-2026)
- 12.10.4 Pfizer Statin Product Portfolio
- 12.10.5 Pfizer Recent Developments
- 12.11 Huizhi
- 12.11.1 Huizhi Company Information
- 12.11.2 Huizhi Business Overview
- 12.11.3 Huizhi Revenue in Statin Business (2021-2026)
- 12.11.4 Huizhi Statin Product Portfolio
- 12.11.5 Huizhi Recent Developments
- 12.12 China Resources Double-Crane Pharmaceutical
- 12.12.1 China Resources Double-Crane Pharmaceutical Company Information
- 12.12.2 China Resources Double-Crane Pharmaceutical Business Overview
- 12.12.3 China Resources Double-Crane Pharmaceutical Revenue in Statin Business (2021-2026)
- 12.12.4 China Resources Double-Crane Pharmaceutical Statin Product Portfolio
- 12.12.5 China Resources Double-Crane Pharmaceutical Recent Developments
- 12.13 North China Pharmaceutical
- 12.13.1 North China Pharmaceutical Company Information
- 12.13.2 North China Pharmaceutical Business Overview
- 12.13.3 North China Pharmaceutical Revenue in Statin Business (2021-2026)
- 12.13.4 North China Pharmaceutical Statin Product Portfolio
- 12.13.5 North China Pharmaceutical Recent Developments
- 12.14 Hanhui Pharmaceutical
- 12.14.1 Hanhui Pharmaceutical Company Information
- 12.14.2 Hanhui Pharmaceutical Business Overview
- 12.14.3 Hanhui Pharmaceutical Revenue in Statin Business (2021-2026)
- 12.14.4 Hanhui Pharmaceutical Statin Product Portfolio
- 12.14.5 Hanhui Pharmaceutical Recent Developments
- 12.15 Daiichi Sankyo
- 12.15.1 Daiichi Sankyo Company Information
- 12.15.2 Daiichi Sankyo Business Overview
- 12.15.3 Daiichi Sankyo Revenue in Statin Business (2021-2026)
- 12.15.4 Daiichi Sankyo Statin Product Portfolio
- 12.15.5 Daiichi Sankyo Recent Developments
- 12.16 Beijing Jialin Pharmaceutical
- 12.16.1 Beijing Jialin Pharmaceutical Company Information
- 12.16.2 Beijing Jialin Pharmaceutical Business Overview
- 12.16.3 Beijing Jialin Pharmaceutical Revenue in Statin Business (2021-2026)
- 12.16.4 Beijing Jialin Pharmaceutical Statin Product Portfolio
- 12.16.5 Beijing Jialin Pharmaceutical Recent Developments
- 12.17 AstraZeneca
- 12.17.1 AstraZeneca Company Information
- 12.17.2 AstraZeneca Business Overview
- 12.17.3 AstraZeneca Revenue in Statin Business (2021-2026)
- 12.17.4 AstraZeneca Statin Product Portfolio
- 12.17.5 AstraZeneca Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst